Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.
Clinical pharmacodynamic evaluation is a key component of the "pharmacologic audit trail" in oncology drug development. We posit that its value can and should be greatly enhanced via application of a robust quantitative pharmacology framework informed by biologically mechanistic considerations. Herein, we illustrate examples of intersectional blindspots across the disciplines of quantitative pharmacology and translational science and offer a roadmap aimed at enhancing the caliber of clinical pharmacodynamic research in the development of oncology therapeutics.
Quantitative Clinical Pharmacology, Takeda Pharmaceuticals International Co, Cambridge, Massachusetts, USA.
K
K
Venkatakrishnan
Translational and Biomarker Research, Takeda Pharmaceuticals International Co, Cambridge, Massachusetts, USA.
J A
JA
Ecsedy
D000970:Antineoplastic Agents / Q000494:pharmacology*; D035843:Biomedical Research / Q000379:methods; D002986:Clinical Trials as Topic / Q000379:methods; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D057170:Translational Research, Biomedical / Q000379:methods
D000970:Antineoplastic Agents